For fiscal 2025 (ended Dec 31, 2025), Compugen Ltd. reported $72.76M of revenue and $35.34M of net income.
CGEN revenue was $72.76M for fiscal 2025 (ended Dec 31, 2025), up 161.1% from fiscal 2024. Compound annual growth was +105.2% over 5 years and +22.9% over 10 years. It rose in 4 of the last 5 fiscal years. Fiscal 2025 is the highest of the 12 fiscal years on file.
CGEN net income was $35.34M for fiscal 2025 (ended Dec 31, 2025), compared with -$14.23M in fiscal 2024. Fiscal 2025 is the highest of the 15 fiscal years on file.
CGEN diluted EPS was $0.38 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.16 in fiscal 2024.
CGEN free cash flow was $31.33M for fiscal 2025 (ended Dec 31, 2025), down 36.7% from fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.76M | $27.86M | $33.46M | $7.50M | $6.00M | $2.00M | - | $17.80M | - | $712.0K |
| Cost of revenue | $9.25M | $7.93M | $2.00M | $975.0K | $680.0K | $60.0K | - | $1.03M | - | $223.0K |
| Gross profit | $63.51M | $19.93M | $31.45M | $6.53M | $5.32M | $1.94M | - | $16.77M | - | $489.0K |
| Research and development | $22.76M | $24.81M | $34.47M | $30.65M | $28.69M | $22.76M | $19.82M | $30.32M | $28.58M | $24.55M |
| Selling, general and admin | $8.89M | $9.44M | $9.73M | $10.32M | $10.86M | $9.80M | $8.41M | $8.04M | $7.63M | $7.35M |
| Operating income | $31.33M | -$14.89M | -$12.99M | -$35.37M | -$35.07M | -$31.50M | -$28.88M | -$23.23M | -$37.41M | -$32.58M |
| Pre-tax income | $35.40M | -$9.71M | -$9.78M | -$33.64M | -$34.20M | -$29.70M | -$28.06M | -$22.60M | -$37.07M | -$31.49M |
| Income tax | $54.0K | $4.52M | $8.97M | $58.0K | $0 | $0 | -$722.0K | - | - | $20.0K |
| Net income | $35.34M | -$14.23M | -$18.75M | -$33.69M | -$34.20M | -$29.70M | -$27.34M | -$22.60M | -$37.07M | -$31.51M |
| EPS, basic | $0.38 | -$0.16 | -$0.21 | -$0.39 | -$0.41 | -$0.37 | -$0.43 | -$0.41 | -$0.72 | -$0.62 |
| EPS, diluted | $0.38 | -$0.16 | -$0.21 | -$0.39 | -$0.41 | -$0.37 | -$0.43 | -$0.41 | -$0.72 | -$0.62 |
| Diluted shares | 93.8M | 89.5M | 87.6M | 86.6M | 84.2M | 79.6M | 63.6M | 55.3M | 51.2M | 50.9M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $90.60M | $18.23M | $13.89M | $11.42M | $8.51M | $7.81M | $9.84M | $6.47M | $26.52M | $10.70M |
| Short-term investments | $9.28M | $23.63M | $11.74M | $0 | - | - | - | - | - | - |
| Receivables | - | $0 | $61.00M | $0 | - | $2.00M | - | - | - | - |
| Current assets | $148.02M | $106.00M | $114.58M | $86.13M | $123.22M | $129.09M | $45.00M | $46.58M | $31.18M | $62.68M |
| Total assets | $156.57M | $115.00M | $121.33M | $94.18M | $132.16M | $138.32M | $53.76M | $53.18M | $38.75M | $71.14M |
| Current liabilities | $22.57M | $20.16M | $26.27M | $11.92M | $17.10M | $10.52M | $6.82M | $9.99M | $6.19M | $4.74M |
| Shareholders' equity | $102.73M | $54.91M | $65.56M | $77.68M | $106.69M | $119.78M | $38.32M | $37.24M | $29.30M | $63.52M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $31.63M | $49.60M | -$35.89M | -$34.11M | -$22.69M | -$28.32M | -$27.89M | -$13.29M | -$30.66M | -$19.82M |
| Capital expenditures | $306.0K | $118.0K | $172.0K | $477.0K | $292.0K | $166.0K | $155.0K | $158.0K | $385.0K | $2.60M |
| Free cash flow | $31.33M | $49.49M | -$36.06M | -$34.59M | -$22.98M | -$28.49M | -$28.04M | -$13.45M | -$31.04M | -$22.42M |
| Investing cash flow | $30.00M | -$46.25M | $35.51M | $37.06M | $6.62M | -$82.17M | $5.33M | -$35.16M | $46.27M | $16.21M |
| Financing cash flow | $10.60M | $554.0K | $3.08M | $353.0K | $16.84M | $108.46M | $25.93M | $28.40M | $201.0K | $2.46M |
| Stock-based compensation | $1.88M | $3.02M | $3.55M | $4.33M | $4.28M | $2.77M | $2.41M | $2.17M | $2.63M | $3.08M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 161.1% | -16.7% | 346.1% | 25.0% | 200.0% | - | - | - | - | -92.3% |
| Gross margin | 87.3% | 71.5% | 94.0% | 87.0% | 88.7% | 97.0% | - | 94.2% | - | 68.7% |
| Operating margin | 43.1% | -53.4% | -38.8% | -471.7% | -584.6% | -1574.8% | - | -130.5% | - | -4576.3% |
| Net margin | 48.6% | -51.1% | -56.1% | -449.3% | -570.0% | -1484.9% | - | -127.0% | - | -4425.0% |
| Free cash flow margin | 43.1% | 177.6% | -107.8% | -461.2% | -383.0% | -1424.3% | - | -75.6% | - | -3148.6% |
| Return on equity | 34.4% | -25.9% | -28.6% | -43.4% | -32.1% | -24.8% | -71.3% | -60.7% | -126.5% | -49.6% |
| Return on assets | 22.6% | -12.4% | -15.5% | -35.8% | -25.9% | -21.5% | -50.8% | -42.5% | -95.7% | -44.3% |
| Current ratio | 6.56 | 5.26 | 4.36 | 7.23 | 7.21 | 12.27 | 6.60 | 4.66 | 5.03 | 13.22 |
Source: XBRL data Compugen Ltd. files with the SEC, latest filing dated Mar 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CGEN | $72.76M | +161.1% | $35.34M | 48.6% | $197.7M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $211.94B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.49B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $60.30B |
| RVMD | $0 | - | -$1.13B | - | $41.76B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.44B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.91B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.22B |